Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Vista Gen Therapeutics, Inc. announced it raised $1.93 Million in an initial filing from an offering of $10 Million
PUBLIC · VTGNAug 06, 2015•about 11 years ago
Amount Raised
$1.93 Million
Round Type
Venture - Series Unknown
South San FranciscoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma
Company Information
Company
VistaGen
Location
343 Allerton Avenue
South San Francisco, California, United States
About
Vistagen is a late clinical-stage biopharmaceutical company headquartered in South San Francisco, CA, developing and commercializing a new class of intranasal product candidates called pherines. Leveraging advanced insights into nose-to-brain neurocircuitry, Vistagen designs pherines to selectively activate peripheral nasal chemosensory receptors and rapidly trigger olfactory bulb–to-brain pathways that influence behavior and autonomic nervous system activity. Because they are engineered to work without entering the bloodstream or brain, pherines have the potential to offer safer therapeutic alternatives to existing pharmacological treatments if successfully developed and approved.
Don't miss VistaGen's next move
Get an email the moment VistaGen raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contact
Verified contacts24 people are listed at VistaGen. We don't have their email yet.
South San FranciscoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma